Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain

Authors: Gonzalo López-Abente, Sergio Mispireta, Marina Pollán

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Breast cancer in women and prostate cancer are the first and second leading tumour respectively in terms of incidence world-wide. Our objective is to ascertain the similarities and differences between mortality trends in breast cancer among women and prostate cancer in Spain using age-period-cohort models, and analyse the correlation between incidence of breast and prostate cancer at cancer registries locally and world-wide.

Methods

We analysed the independent effects of age, period of death and birth cohort on mortality rates for breast cancer in women and prostate cancer in Spain across the period 1952–2011. Segmented regression analyses were performed to detect and estimate changes in period and cohort curvatures. Correlation among age-adjusted incidence rates at 246 population cancer registries world-wide was analysed for the period 2003–2007.

Results

The mortality trend displayed common characteristics in terms of the annual number of deaths due to these tumours, their adjusted mortality rates and the change points detected in the cohort and period effects. The trend in incidence was very different to that in mortality, due to early detection and progressive improvement in survival. Correlation between the incidence rates of both tumours recorded by registries around the world proved to be a generalised phenomenon.

Conclusions

This study shows that breast cancer mortality in women and prostate cancer mortality and their trends in Spain display visible similarities in terms of the number of deaths due to these tumours, their adjusted mortality rates and the changes experienced by mortality over time. The effects of advances in the diagnosis of both tumours correspond to a decline in mortality which becomes evident after a lag of approximately eight years. Correlation between breast and prostate cancer incidence rates is very high in Spain and at registries on all continents.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D: GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer
2.
Mandal R, St-Hilaire S, Kie JG, Derryberry D: Spatial trends of breast and prostate cancers in the United States between 2000 and 2005. Int J Health Geogr. 2009, 8: 53-10.1186/1476-072X-8-53.CrossRefPubMedPubMedCentral
3.
Mistry M, Parkin DM, Ahmad AS, Sasieni P: Cancer incidence in the United Kingdom: projections to the year 2030. Br J Cancer. 2011, 105: 1795-1803. 10.1038/bjc.2011.430.CrossRefPubMedPubMedCentral
4.
López-Otín C, Diamandis EP: Breast and prostate cancer: an analysis of common epidemiological, genetic, and biochemical features. Endocr Rev. 1998, 19: 365-396.PubMed
5.
Cuzick J: Hormone replacement therapy and the risk of breast cancer. Eur J Cancer. 2008, 44: 2344-2349. 10.1016/j.ejca.2008.07.041.CrossRefPubMed
6.
7.
Prentice RL, Sheppard L: Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control. 1990, 1: 81-97. 10.1007/BF00053187. discussion 99–109CrossRefPubMed
8.
Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Fletcher O, Peto J, Gibson L, Dos Santos Silva I, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Czene K, Irwanto A, Liu J, Waisfisz Q, Meijers-Heijboer H, Adank M, Breast and Ovarian Cancer Susceptibility Collaboration, et al: Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013, 45: 353-361. 10.1038/ng.2563. 361e1–2CrossRefPubMedPubMedCentral
9.
Eeles RA, Olama AAA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, et al: Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet. 2013, 45: 385-391. 10.1038/ng.2560. 391e1–2CrossRefPubMed
10.
Larrañaga N, Galceran J, Ardanaz E, Franch P, Navarro C, Sánchez MJ, Pastor-Barriuso R, Prostate Cancer Working Group: Prostate cancer incidence trends in Spain before and during the prostate-specific antigen era: impact on mortality. Ann Oncol. 2010, 21 (Suppl 3): iii83-iii89.PubMed
11.
Pollán M, Pastor-Barriuso R, Ardanaz E, Argüelles M, Martos C, Galcerán J, Sánchez-Pérez M-J, Chirlaque M-D, Larrañaga N, Martínez-Cobo R, Tobalina M-C, Vidal E, Marcos-Gragera R, Mateos A, Garau I, Rojas-Martín M-D, Jiménez R, Torrella-Ramos A, Perucha J, Pérez-de-Rada M-E, González S, Rabanaque M-J, Borràs J, Navarro C, Hernández E, Izquierdo A, López-Abente G, Martínez C: Recent changes in breast cancer incidence in Spain, 1980–2004. J Natl Cancer Inst. 2009, 101: 1584-1591. 10.1093/jnci/djp358.CrossRefPubMedPubMedCentral
12.
Holford TR: Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health. 1991, 12: 425-457. 10.1146/annurev.pu.12.050191.002233.CrossRefPubMed
13.
Dean C: Testing for overdispersion in Poisson and binomial regression models. J Am Stat Assoc. 1992, 87: 451-457. 10.1080/01621459.1992.10475225.CrossRef
14.
Muggeo VMR: Estimating regression models with unknown break-points. Stat Med. 2003, 22: 3055-3071. 10.1002/sim.1545.CrossRefPubMed
15.
R Development Core Team: R: A Language and Environment for Statistical Computing. 2005, Vienna, Austria: R Foundation for Statistical Computing
16.
Forman D, Bray F, Brewster D, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher M, Swaminathan R, Ferlay J: Cancer Incidence in Five Continents Vol. X, Volume 164. 2013, Lyon: IARC Scientific Publications
17.
Ascunce N, Salas D, Zubizarreta R, Almazán R, Ibáñez J, Ederra M, Network of Spanish Cancer Screening Programmes (Red de Programas Espanoles de Cribado de Cancer): Cancer screening in Spain. Ann Oncol. 2010, 21 (Suppl 3): iii43-iii51.PubMed
18.
Martinez-Alonso M, Vilaprinyo E, Marcos-Gragera R, Rue M: Breast cancer incidence and overdiagnosis in Catalonia (Spain). Breast Cancer Res BCR. 2010, 12: R58-10.1186/bcr2620.CrossRefPubMed
19.
Puliti D, Duffy SW, Miccinesi G, de Koning H, Lynge E, Zappa M, Paci E, EUROSCREEN Working Group: Overdiagnosis in mammographic screening for breast cancer in Europe: a literature review. J Med Screen. 2012, 19 (Suppl 1): 42-56.CrossRefPubMed
20.
Páez A, Luján M, Llanes L, Romero I, de la Cal MA, Miravalles E, Berenguer A: PSA-use in a Spanish industrial area. Eur Urol. 2002, 41: 162-166. 10.1016/S0302-2838(01)00022-7.CrossRefPubMed
21.
Cepeda Piorno J, Rivas del Fresno M, Fuente Martín E, González García E, Muruamendiaraz Fernández V, Fernández Rodríguez E: [Advantages and risks of the use of prostate-specific antigen (PSA) in the health-care area No. 4 of Gijon (Asturias)]. Arch Esp Urol. 2005, 58: 403-411.CrossRefPubMed
22.
De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R: EUROCARE-5 Working Group: Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE–5-a population-based study. Lancet Oncol. 2014, 15: 23-34. 10.1016/S1470-2045(13)70546-1.CrossRefPubMed
23.
24.
Autier P, Boniol M, Gavin A, Vatten LJ: Breast cancer mortality in neighbouring European countries with different levels of screening but similar access to treatment: trend analysis of WHO mortality database. BMJ. 2011, 343: d4411-10.1136/bmj.d4411.CrossRefPubMedPubMedCentral
25.
Martín M, Pollán M, Jara C, López-Tarruella S, Carrasco E: Proyecto EL Álamo III. Encuesta de evolución de pacientes con cáncer de mama en hospitales del grupo GEICAM 1998–2001. 2014, Madrid: GEICAM
26.
Chen Y-C, Page JH, Chen R, Giovannucci E: Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate. 2008, 68: 1582-1591. 10.1002/pros.20825.CrossRefPubMedPubMedCentral
27.
Sakoda LC, Jorgenson E, Witte JS: Turning of COGS moves forward findings for hormonally mediated cancers. Nat Genet. 2013, 45: 345-348. 10.1038/ng.2587.CrossRefPubMed
28.
Pharoah PDP, Tsai Y-Y, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, Vincent D, Cunningham JM, Dennis J, Dicks E, Aben KK, Anton-Culver H, Antonenkova N, Armasu SM, Baglietto L, Bandera EV, Beckmann MW, Birrer MJ, Australian Cancer Study, Australian Ovarian Cancer Study Group, et al: GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet. 2013, 45: 362-370. 10.1038/ng.2564.CrossRefPubMedPubMedCentral
29.
Pike MC, Pearce CL, Wu AH: Prevention of cancers of the breast, endometrium and ovary. Oncogene. 2004, 23: 6379-6391. 10.1038/sj.onc.1207899.CrossRefPubMed
30.
World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. 2007, Washington DC: AICR
31.
Hsing AW, Sakoda LC, Chua S: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007, 86: s843-s857.PubMed
32.
Patel AV, Rodriguez C, Jacobs EJ, Solomon L, Thun MJ, Calle EE: Recreational physical activity and risk of prostate cancer in a large cohort of U.S. men. Cancer Epidemiol Biomark Prev. 2005, 14: 275-279.CrossRef
33.
World Cancer Research Fund / American Institute for Cancer Research: Colorectal Cancer 2011 Report. Food, Nutrition, Physical Activity, and the Prevention of Colorectal Cancer. 2011, Washington DC: AICR
34.
Alexander DD, Morimoto LM, Mink PJ, Cushing CA: A review and meta-analysis of red and processed meat consumption and breast cancer. Nutr Res Rev. 2010, 23: 349-365. 10.1017/S0954422410000235.CrossRefPubMed
35.
Castelló A, Pollán M, Buijsse B, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Ramos M, Muñoz M, Lluch A, de Juan-Ferré A, Jara C, Jimeno MA, Rosado P, Díaz E, Guillem V, Carrasco E, Pérez-Gómez B, Vioque J, Boeing H, Martín M: Spanish Mediterranean diet and other dietary patterns and breast cancer risk: case–control EpiGEICAM study. Br J Cancer. 2014, 111: 1454-1462. 10.1038/bjc.2014.434.CrossRefPubMedPubMedCentral
36.
Key TJ, Chen J, Wang DY, Pike MC, Boreham J: Sex hormones in women in rural China and in Britain. Br J Cancer. 1990, 62: 631-636. 10.1038/bjc.1990.344.CrossRefPubMedPubMedCentral
Metadata
Title
Breast and prostate cancer: an analysis of common epidemiological features in mortality trends in Spain
Authors
Gonzalo López-Abente
Sergio Mispireta
Marina Pollán
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-874

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

MicroRNA profile in very young women with breast cancer

Research article

Differential knockdown of TGF-β ligands in a three-dimensional co-culture tumor- stromal interaction model of lung cancer

Research article

FHL1C induces apoptosis in notch1-dependent T-ALL cells through an interaction with RBP-J

Research article

Clinicopathological features and EGFR gene mutation status in elderly patients with resected non–small-cell lung cancer

Research article

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells

Research article

Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits